TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX) has received an average rating of “Hold” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $6.60.

Several equities research analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a report on Thursday, January 22nd. Needham & Company LLC decreased their price objective on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 4th. Morgan Stanley cut shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research note on Friday, November 14th. BTIG Research lowered shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 4th. Finally, HC Wainwright lowered their price objective on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, November 13th.

TScan Therapeutics Trading Up 4.6%

NASDAQ TCRX opened at $1.02 on Thursday. TScan Therapeutics has a one year low of $0.88 and a one year high of $2.57. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.44 and a current ratio of 6.44. The company has a market capitalization of $57.89 million, a price-to-earnings ratio of -0.91 and a beta of 1.04. The company’s 50-day simple moving average is $1.04 and its two-hundred day simple moving average is $1.45.

Insider Buying and Selling at TScan Therapeutics

In related news, major shareholder Lynx1 Capital Management Lp acquired 75,500 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was acquired at an average price of $0.90 per share, with a total value of $67,950.00. Following the acquisition, the insider directly owned 8,012,916 shares in the company, valued at $7,211,624.40. This represents a 0.95% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have acquired a total of 161,801 shares of company stock valued at $145,621 in the last quarter. 4.35% of the stock is owned by corporate insiders.

Institutional Trading of TScan Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd purchased a new position in shares of TScan Therapeutics in the second quarter valued at approximately $26,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of TScan Therapeutics in the second quarter valued at about $29,000. Quadrature Capital Ltd acquired a new stake in shares of TScan Therapeutics in the second quarter valued at about $33,000. Boothbay Fund Management LLC lifted its stake in shares of TScan Therapeutics by 50.0% in the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after buying an additional 8,121 shares in the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in TScan Therapeutics during the fourth quarter worth about $25,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.